1040720-25-9Relevant academic research and scientific papers
N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate
Zanaletti, Riccardo,Bettinetti, Laura,Castaldo, Cristiana,Ceccarelli, Ilaria,Cocconcelli, Giuseppe,Comery, Thomas A.,Dunlop, John,Genesio, Eva,Ghiron, Chiara,Haydar, Simon N.,Jow, Flora,Maccari, Laura,Micco, Iolanda,Nencini, Arianna,Pratelli, Carmela,Scali, Carla,Turlizzi, Elisa,Valacchi, Michela
supporting information, p. 10277 - 10281 (2013/01/16)
α7 nicotinic acetylcholine receptors (α7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the α7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.
ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
-
Page/Page column 209, (2010/04/03)
The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a
NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS
-
Page/Page column 144; 171, (2008/12/07)
The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.
